0U9 is found in 1 entries

0U9 as free ligands, exist in 1 entries. Examples include 4FIA,

Find related ligands: Stereoisomers Similar ligands Chemical Structure Search

View summary at Ligand Expo

Chemical Component Summary

Name S-bicalutamide
Identifiers (2S)-N-[4-cyano-3-(trifluoromethyl)phenyl]-3-[(4-fluorophenyl)sulfonyl]-2-hydroxy-2-methylpropanamide
Formula C18 H14 F4 N2 O4 S
Molecular Weight 430.37 g/mol
Type non-polymer
Isomeric SMILES C[C@@](O)(CS(=O)(=O)c1ccc(F)cc1)C(=O)Nc1ccc(C#N)c(c1)C(F)(F)F
InChI InChI=1S/C18H14F4N2O4S/c1-17(26,10-29(27,28)14-6-3-12(19)4-7-14)16(25)24-13-5-2-11(9-23)15(8-13)18(20,21)22/h2-8,26H,10H2,1H3,(H,24,25)/t17-/m1/s1

Chemical Details

Formal Charge 0
Atom Count 43
Chiral Atom Count 1
Chiral Atoms C16
Bond Count 44
Aromatic Bond Count 12

Drug Info: DrugBank

DrugBank ID DB01128   (Different stereochemistry)
Name Bicalutamide
Groups approved
Description Bicalutamide is an oral non-steroidal anti-androgen for prostate cancer. It binds to the androgen receptor.
Synonyms Casodex
Brand Names
  • Accel-bicalutamide Tablets USP
  • Ach-bicalutamide
  • Act Bicalutamide
  • Ag-bicalutamide
  • Apo-bicalutamide
  • Ava-bicalutamide
  • Bicalutamide
  • Bicalutamide Tablets
  • Casodex
  • Casodex Tab 50mg
  • Dom-bicalutamide
  • Jamp-bicalutamide
  • Med-bicalutamide
  • Mylan-bicalutamide
  • Nu-bicalutamide
  • PHL-bicalutamide
  • PMS-bicalutamide
  • Pro-bicalutamide - 50
  • Ran-bicalutamide
  • Ratio-bicalutamide
  • Sandoz Bicalutamide
  • Teva-bicalutamide
  • Van-bicalutamide
Affected Organism Humans and other mammals
Indication For treatment (together with surgery or LHRH analogue) of advanced prostatic cancer.
Pharmacology Bicalutamide is an antineoplastic hormonal agent primarily used in the treatment of prostate cancer. Bicalutamide is a pure, nonsteroidal anti-androgen with affinity for androgen receptors (but not for progestogen, estrogen, or glucocorticoid receptors). Consequently, Bicalutamide blocks the action of androgens of adrenal and testicular origin which stimulate the growth of normal and malignant prostatic tissue. Prostate cancer is mostly androgen-dependent and can be treated with surgical or chemical castration. To date, antiandrogen monotherapy has not consistently been shown to be equivalent to castration.
Mechanism of action Bicalutamide competes with androgen for the binding of androgen receptors, consequently blocking the action of androgens of adrenal and testicular origin which stimulate the growth of normal and malignant prostatic tissue.
Route of administration oral
ATC-Code L02BB03
AHFS-Code 10:00.00
CAS number 90357-06-5

Drug Targets

Name Sequence Search Pharmacological Action Actions
Androgen receptor ,Androgen receptor"> Search yes antagonist
Drug Info/Drug Targets: DrugBank 3.0: a comprehensive resource for 'omics' research on drugs. Knox C, Law V, Jewison T, Liu P, Ly S, Frolkis A, Pon A, Banco K, Mak C, Neveu V, Djoumbou Y, Eisner R, Guo AC, Wishart DS. Nucleic Acids Res. 2011 Jan; 39 (Database issue):D1035-41. | PMID: 21059682